
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp is demonstrating promising advancements in its clinical studies, particularly with the MAD study expected to yield significant initial efficacy data by the second half of 2026, indicating potential growth in novel therapeutics with ABS-201. The revised net present value (rNPV) of $1.6 billion reflects growing confidence in Absci's product pipeline, driven by preclinical evidence supporting the unique mechanism of action of ABS-201. Additionally, the strong interest in in-office procedures among potential users enhances the commercial outlook, positioning the company favorably as it approaches critical data releases.
Bears say
The financial analysis indicates several significant risks that may adversely affect Absci Corp's stock performance, including potential challenges related to partnerships, technology development, clinical trials, regulatory hurdles, commercial viability, legal issues, intellectual property, competition, and shareholder dilution. The lack of standard of care in endo, particularly for non-hormonal treatment options, may hinder the company's ability to effectively market its products. Additionally, with patients often opting for more permanent solutions due to high treatment burdens, the company's market for such biologics could face limitations in growth and acceptance.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares